Related Experiment Video
Updated: Jun 5, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast
Xiuping Guo1, Wensheng Zheng2, Kaichao Song1
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Abstract:
In triple-negative breast cancer (TNBC), chemotherapy-induced immunogenic cell death (ICD) often fails to trigger truly effective antitumor immunity. This failure primarily stems from the simultaneous release of damage-associated molecular patterns (DAMPs) and immunosuppressive prostaglandin E2 (PGE2), creating an intrinsic NOT-AND signaling conflict. This barrier hinders efficient immune priming, a response rarely induced by conventional chemotherapy. To address this conflict while minimizing toxicity, R-Gem@Cel-PV, a spatiotemporally programmed nanovesicle, was designed to impose both spatial localization and sequential signal control within the tumor microenvironment. Following preferential accumulation in tumor tissue, enzymatic disassembly of the nanomedicine triggers the rapid release of celecoxib to suppress local PGE2 signaling and alleviate immune suppression. Subsequently, the delayed activation of a phospholipid-gemcitabine prodrug induces DAMP-releasing cell death. This temporal decoupling-unachievable with free drug combinations-converts gemcitabine from a weak ICD inducer into a potent one. In TNBC models, R-Gem@Cel-PV boosted dendritic cell maturation, orchestrated a robust antitumor immune response, and significantly inhibited both primary tumor growth and metastasis. These findings demonstrate that resolving the immunosignal conflict through precise spatiotemporal control is essential for effective immune engagement in TNBC and offer a generalizable strategy for reprogramming the immune response to chemotherapy in immune-refractory tumors.
Insights
New nanomedicine R-Gem@Cel-PV overcomes chemotherapy resistance in triple-negative breast cancer (TNBC) by controlling immune signals. This strategy enhances antitumor immunity and inhibits tumor growth and metastasis.
Area of Science:
- Oncology
- Immunology
- Nanomedicine
Background:
- Chemotherapy-induced immunogenic cell death (ICD) in triple-negative breast cancer (TNBC) often fails to generate effective antitumor immunity.
- This failure is due to the simultaneous release of damage-associated molecular patterns (DAMPs) and immunosuppressive prostaglandin E2 (PGE2), creating a signaling conflict that hinders immune priming.
Purpose of the Study:
- To design a nanomedicine (R-Gem@Cel-PV) that resolves the signaling conflict and enhances immune response in TNBC.
- To investigate the spatiotemporal control of DAMPs and PGE2 release for improved ICD and antitumor immunity.
Main Methods:
- Development of R-Gem@Cel-PV, a nanovesicle for spatiotemporal control of drug release within the tumor microenvironment.
- Enzymatic disassembly of nanomedicine to sequentially release celecoxib (PGE2 inhibitor) and a gemcitabine prodrug (DAMP inducer).
- Evaluation of R-Gem@Cel-PV in TNBC models for its effects on dendritic cell maturation, immune response, tumor growth, and metastasis.
Main Results:
- R-Gem@Cel-PV successfully suppressed local PGE2 signaling and induced DAMP-releasing cell death through temporal decoupling.
- The nanomedicine significantly boosted dendritic cell maturation and orchestrated a robust antitumor immune response.
- R-Gem@Cel-PV demonstrated significant inhibition of primary tumor growth and metastasis in TNBC models.
Conclusions:
- Resolving the immunosignal conflict via precise spatiotemporal control is crucial for effective immune engagement in TNBC.
- R-Gem@Cel-PV strategy effectively reprograms the immune response to chemotherapy in immune-refractory tumors.
- This approach offers a generalizable strategy for enhancing chemotherapy efficacy in challenging cancers.
